FALCINELLI, FLAVIO
FALCINELLI, FLAVIO
Mostra
records
Risultati 1 - 3 di 3 (tempo di esecuzione: 0.01 secondi).
Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab
2023 Ubaldi, M.; Sergi, M. C.; Falcinelli, F.; Mandala', M.
Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse
2005 Aversa, Franco; Terenzi, Adelmo; Tabilio, Antonio; Falzetti, Franca; Carotti, Alessandra; Ballanti, Stelvio; Felicini, Rita; Falcinelli, Flavio; Velardi, Andrea; Ruggeri, Loredana; Aloisi, Teresa; Saab, JEAN PIERRE ANTONIOS; Santucci, Antonella; Perruccio, Katia; Martelli, Maria Paola; Mecucci, Cristina; Reisner, Yair; Martelli, Massimo Fabrizio
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients
2023 Schiaroli, E; Gidari, A; Brachelente, G; Bicchieraro, G; Spaccapelo, R; Bastianelli, S; Pierucci, S; Busti, C; Pallotto, C; Malincarne, L; Camilloni, B; Falcinelli, F; De Socio, Gv; Villa, A; Mencacci, A; Francisci, D
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Delayed cold-type autoimmune hemolytic anemia responding to Rituximab in a melanoma patient treated with Ipilimumab and Nivolumab | 2023 | Ubaldi, M.; Sergi, M. C.; Falcinelli, F.; Mandala', M. | |
| Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse | 2005 | Aversa, Franco; Terenzi, Adelmo; Tabilio, Antonio; Falzetti, Franca; Carotti, Alessandra; Ballanti, Stelvio; Felicini, Rita; Falcinelli, Flavio; Velardi, Andrea; Ruggeri, Loredana; Aloisi, Teresa; Saab, JEAN PIERRE ANTONIOS; Santucci, Antonella; Perruccio, Katia; Martelli, Maria Paola; Mecucci, Cristina; Reisner, Yair; Martelli, Massimo Fabrizio | |
| Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients | 2023 | Schiaroli, E; Gidari, A; Brachelente, G; Bicchieraro, G; Spaccapelo, R; Bastianelli, S; Pierucci, S; Busti, C; Pallotto, C; Malincarne, L; Camilloni, B; Falcinelli, F; De Socio, Gv; Villa, A; Mencacci, A; Francisci, D |